Literature DB >> 11275884

First endoscopic-histologic follow-up in patients with body-predominant atrophic gastritis: when should it be done?

E Lahner1, P Caruana, G D'Ambra, G Ferraro, E Di Giulio, G Delle Fave, C Bordi, B Annibale.   

Abstract

BACKGROUND: Body-predominant atrophic gastritis is considered a risk factor for gastric cancer and carcinoid. Timing of follow-up for patients with this disorder has not been defined. This study was undertaken to determine the optimal time for the first endoscopic/histologic follow-up in patients with body-predominant atrophic gastritis.
METHODS: Forty-two patients with body-predominant atrophic gastritis were randomly assigned to 1 of 2 follow-up intervals: group A (n = 22) at 24 months and group B (n = 20) at 48 months. At baseline and follow-up patients underwent gastroscopy at which biopsies were obtained from the antrum and body for histopathology and evaluation for enterochromaffin-like cells.
RESULTS: In group A patients, 2 antral hyperplastic polyps (9.1%) were present at baseline and 4 antral hyperplastic polyps (18.2%) were found at follow-up. In group B patients, baseline gastroscopy revealed 2 antral hyperplastic polyps (10%) and follow-up 2 antral hyperplastic polyps (10%) and 1 carcinoid tumor (5%) in the body. Atrophy and intestinal metaplasia scores in gastric body and antral mucosa in both groups did not change significantly between baseline and follow-up, except an increase in antral mucosa atrophy in group B patients (p = 0.02) was revealed.
CONCLUSIONS: The results of this study indicate that performing the first follow-up in patients with body-predominant atrophic gastritis need not be earlier than at 4 years after diagnosis. This interval is satisfactory for detection of potential neoplastic lesions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11275884     DOI: 10.1067/mge.2001.112189

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  11 in total

1.  Timing and sampling in surveillance of premalignant gastric lesions.

Authors:  G Capurso; E Lahner; G Delle Fave; B Annibale
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

Review 2.  Diagnosis and management of pernicious anemia.

Authors:  Bruno Annibale; Edith Lahner; Gianfranco Delle Fave
Journal:  Curr Gastroenterol Rep       Date:  2011-12

3.  Surveillance strategy of atrophic gastritis and intestinal metaplasia in a country with a high prevalence of gastric cancer.

Authors:  Woon Geon Shin; Heung Up Kim; Ho June Song; Su Jin Hong; Ki-Nam Shim; In-Kyung Sung; Jae Gyu Kim
Journal:  Dig Dis Sci       Date:  2011-10-08       Impact factor: 3.199

4.  Successful type-oriented endoscopic resection for gastric carcinoid tumors: A case report.

Authors:  Shouji Shimoyama; Mitsuhiro Fujishiro; Yutaka Takazawa
Journal:  World J Gastrointest Endosc       Date:  2010-12-16

Review 5.  Pathology of non-Helicobacter pylori gastritis: extending the histopathologic horizons.

Authors:  Gregory Y Lauwers; Hiroshi Fujita; Koji Nagata; Michio Shimizu
Journal:  J Gastroenterol       Date:  2009-12-05       Impact factor: 7.527

6.  Laparoscopic gastric bypass with subtotal gastrectomy for a super-obese patient with Biermer anemia.

Authors:  Maxime Sodji; Frédéric A Sebag; Jean Marc Catheline
Journal:  Obes Surg       Date:  2007-08       Impact factor: 4.129

Review 7.  Autoimmune atrophic gastritis--pathogenesis, pathology and management.

Authors:  William L Neumann; Elizabeth Coss; Massimo Rugge; Robert M Genta
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-06-18       Impact factor: 46.802

Review 8.  Pernicious anemia: new insights from a gastroenterological point of view.

Authors:  Edith Lahner; Bruno Annibale
Journal:  World J Gastroenterol       Date:  2009-11-07       Impact factor: 5.742

9.  A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia.

Authors:  M Dinis-Ribeiro; C Lopes; A da Costa-Pereira; M Guilherme; J Barbosa; H Lomba-Viana; R Silva; L Moreira-Dias
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

10.  Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma.

Authors:  Mário Dinis-Ribeiro; Altamiro da Costa-Pereira; Carlos Lopes; Joana Barbosa; Mateus Guilherme; Luís Moreira-Dias; Helena Lomba-Viana; Rui Silva; Nuno Abreu; Rafael Lomba-Viana
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.